These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 31765822)

  • 21. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation of dopamine D3 receptor.
    Mansour HM; Mohamed AF; Khattab MM; El-Khatib AS
    Brain Res; 2024 Jul; 1834():148893. PubMed ID: 38554797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
    Ahlers-Dannen KE; Spicer MM; Fisher RA
    Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
    Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
    Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease.
    Shen QQ; Jv XH; Ma XZ; Li C; Liu L; Jia WT; Qu L; Chen LL; Xie JX
    Acta Pharmacol Sin; 2024 Feb; 45(2):268-281. PubMed ID: 37674042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
    Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
    Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D3 agonists in the treatment of Parkinson's disease.
    Das B; Modi G; Dutta A
    Curr Top Med Chem; 2015; 15(10):908-26. PubMed ID: 25832718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.
    Ledonne A; Massaro Cenere M; Paldino E; D'Angelo V; D'Addario SL; Casadei N; Nobili A; Berretta N; Fusco FR; Ventura R; Sancesario G; Guatteo E; Mercuri NB
    Mov Disord; 2023 Feb; 38(2):256-266. PubMed ID: 36350188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca(2+) dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat.
    Avalos-Fuentes A; Albarrán-Bravo S; Loya-Lopéz S; Cortés H; Recillas-Morales S; Magaña JJ; Paz-Bermúdez F; Rangel-Barajas C; Aceves J; Erlij D; Florán B
    Neurobiol Dis; 2015 Feb; 74():336-46. PubMed ID: 25517101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calpain activation and progression of inflammatory cycles in Parkinson's disease.
    Gao A; McCoy HM; Zaman V; Shields DC; Banik NL; Haque A
    Front Biosci (Landmark Ed); 2022 Jan; 27(1):20. PubMed ID: 35090325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
    Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
    Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer.
    Bono F; Mutti V; Savoia P; Barbon A; Bellucci A; Missale C; Fiorentini C
    Neurobiol Dis; 2019 Sep; 129():1-12. PubMed ID: 31051233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia.
    Lanza K; Centner A; Coyle M; Del Priore I; Manfredsson FP; Bishop C
    Exp Neurol; 2021 Feb; 336():113534. PubMed ID: 33249031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presynaptic control of [
    Briones-Lizardi LJ; Cortés H; Avalos-Fuentes JA; Paz-Bermúdez FJ; Aceves J; Erlij D; Florán B
    Neuroscience; 2019 May; 406():563-579. PubMed ID: 30930129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dual role of c-src in cell-to-cell transmission of α-synuclein.
    Choi YR; Kim JB; Kang SJ; Noh HR; Jou I; Joe EH; Park SM
    EMBO Rep; 2020 Jul; 21(7):e48950. PubMed ID: 32372484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
    Lao CL; Kuo YH; Hsieh YT; Chen JC
    Neurotox Res; 2013 Nov; 24(4):523-31. PubMed ID: 23820985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
    Szego ÉM; Gerhardt E; Kermer P; Schulz JB
    Neurobiol Dis; 2012 Jan; 45(1):591-600. PubMed ID: 22001606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease.
    Brys I; Nunes J; Fuentes R
    Eur J Neurosci; 2017 Aug; 46(3):1906-1917. PubMed ID: 28370471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.